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Abstract
Background—This study examines the association between microalbuminuria and the
development of proteinuria among HIV-infected persons.
Methods—948 subjects provided urine samples for albumin, protein, and creatinine
measurements semiannually. Microalbuminuria was an albumin-to-creatinine ratio of >30 mg/gm.
Proteinuria was a protein-to-creatinine ratio of ≥0.350 mg/mg. The progression from
microalbuminuria to proteinuria was described.
Results—At baseline, 69.4% had no detectable proteinuria, 20.2% had microalbuminuria, and
10.4% had proteinuria. Subjects with microalbuminuria and proteinuria were more likely to be
black (p=0.03), have lower CD4+ counts (p=0.02,0.0001 compared to subjects without abnormal
proteinuria, respectively), and have a higher HIV RNA level (p=0.08,0.04). Among 658 subjects
with normal urine protein, 82.7% continued to have no abnormality, 14.3% developed
microalbuminuria, and 3.0% developed proteinuria. Subjects without baseline proteinuria (i.e.
either normal protein excretion or microalbuminuria) who developed proteinuria were more likely
to have microalbuminuria (p=0.001), a lower CD4+ count (p=0.06), and a higher plasma HIV
RNA (p=0.03) than those who did not progress to proteinuria. In multivariate analysis, only
microalbuminuria remained associated with the development of proteinuria (OR=2.9; 95% CI 1.5,
5.5; p=0.001).
Conclusion—Microalbuminuria predicts the development of proteinuria among HIV-infected
persons. Because proteinuria has been linked to poorer outcomes, strategies to affect
microalbuminuria should be tested.
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Introduction
Survival among persons with HIV infection has improved significantly over the last decade
(1). Concurrent with these improvements in morbidity and mortality, there has been an
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increase in the proportions of deaths among HIV-infected persons due to liver and kidney
disease (2). As a result, there has been an increasing focus in research and clinical care into
chronic liver and kidney conditions, including an enhanced understanding of their
pathogenesis as long term complications of HIV infection, as toxicities related to the
medications used to treat HIV infection, and as comorbidities in an aging population such as
diabetes mellitus, hypertension, and hyperlipidemia.
Microalbuminuria and proteinuria both serve as markers of glomerular function. An intact
glomerulus will maintain the barrier to filtration between the capillary and urinary spaces
resulting in minimal levels of albumin or protein in the urine. Albumin excretion greater
than 30 mg per day and protein excretion exceeding 350 mg per day are abnormal and
generally signify a process or disease that is affecting this barrier to diffusion.
Among patients with diabetes mellitus, the presence of microalbuminuria is associated with
the risk of developing overt proteinuria and death (3,4,5) and is considered a marker of
progressive kidney disease. These associations suggest that microalbuminuria is likely a
marker of early vascular damage related specifically to abnormal glycosylation in diabetes
mellitus or to more general processes in other chronic illnesses. Among HIV-infected
persons, the presence of proteinuria has been linked to increased risk of chronic kidney
disease (CKD), end stage renal disease (ESRD), new AIDS-defining illness, and mortality
(6,7,8). The association of proteinuria with these outcomes suggests that it might be a
marker of a more diffuse vascular process and that this process might affect outcomes both
within and outside of the kidney. Based on this, the identification of an earlier marker of
patients at higher risk to develop proteinuria could be clinically advantageous. To properly
design and test prevention or treatment strategies to lower the risk associated with
proteinuria similar to those available in diabetic nephropathy (9-12), an understanding of the
natural history of microalbuminuria in HIV is essential. This study was therefore undertaken
to describe the abnormal patterns of urine protein excretion in a large HIV positive cohort
and to test the ability of microalbuminuria to predict the development of overt proteinuria.
Methods
This is a prospective cohort study conducted in the Adult Infectious Diseases Clinics of
Duke University Medical Center (Durham, NC) and the University of North Carolinas
Hospitals (Chapel Hill, NC). This study was approved by the Institutional Review Boards of
both sites. A convenience sample of subjects was enrolled by approaching all patients seen
in the respective ID clinics on a particular day. The day of the week on which subjects were
recruited varied to include patients of multiple providers. All subjects provided informed
consent.
Data Collection
Baseline data collected included gender, age, race, height, weight, systolic and diastolic
blood pressure, most recent CD4+ lymphocyte count and plasma HIV RNA level, and serum
creatinine. Blood pressure measurements were obtained from review of the visit specific
records. Subjects were approached at their routine clinical visit closest temporally to six
month intervals from the date of their baseline exam for a period of two years to provide
additional random (spot or untimed) urine specimens. All measurements for urine albumin,
protein, and creatinine were performed by a single laboratory (LabCorp, Burlington, NC).
Information on hepatitis B and C infection, intravenous drug use, diabetes mellitus and
concomitant medications was not available.
Szczech et al. Page 2














Urine albumin and protein excretion was estimated using the urine albumin to creatinine
ratio and urine protein to creatinine ratio, respectively. Microalbuminuria was defined as an
albumin to creatinine ratio of >= 30 mg/gm (3.5 mg/mmol in SI units). Abnormal protein
excretion was defined as a protein to creatinine ratio of >=0.350 mg/mg. Estimated
glomerular filtration rate (GFR) was calculated using the MDRD formula (13).
For each urine collection, each subject was described as being without abnormal urine
protein excretion (i.e. no microalbuminuria or proteinuria) or as having microalbuminuria or
proteinuria. The demographics and laboratory parameters were described for the cohort
overall based on these groups at baseline evaluation. Values at subsequent time points were
summarized within group. Clinical and demographic differences between groups were
compared using the Chi-square and Student's T-tests for categorical and continuous
variables, respectively.
Each subject with at least one follow up visit was included in the longitudinal analysis. The
first available follow up visit for each subject after their baseline visit was used.
Associations between clinical and demographic variables including age, gender, race,
systolic and diastolic blood pressure, CD4+ lymphocyte count, plasma HIV RNA level, and
GFR and outcomes such as progression to overt proteinuria were estimated using logistic
regression. Multivariable risk ratios were calculated based on model parameter coefficients
using standard methods. Entry and elimination criteria were set at a value of p = 0.10.
All p-values were reported as 2-sided, and all confidence intervals reported were 95%
intervals. All analyses were performed using Stata (version 8.0, College Station, TX).
Results
Nine hundred and forty-eight HIV-infected subjects were enrolled and provided at least one
urine sample (315 at Duke and 633 at UNC). At baseline, 69.4 percent had no detectable
urine protein excretion, 20.2 percent had microalbuminuria, and 10.4 percent had
proteinuria. In general, subjects with microalbuminuria and proteinuria were more likely to
be black (p= 0.02), have a lower CD4+ lymphocyte count (p= 0.02 comparing subjects
without abnormal urine protein excretion to subjects with microalbuminuria, p=0.0001
comparing subjects with microalbuminuria to subjects with proteinuria), and have a higher
plasma HIV RNA level (p= 0.08 comparing subjects without abnormal urine protein
excretion to subjects with microalbuminuria, p=0.04 comparing subjects with
microalbuminuria to subjects with proteinuria) (Table 1). There was no difference in serum
creatinine comparing subjects without abnormal urine protein excretion to subjects with
microalbuminuria (p= 0.31); however, subjects with proteinuria had a lower GFR than
subjects with microalbuminuria (p= 0.03). At baseline, a greater proportion of subjects with
microalbuminuria or proteinuria had an eGFR< 90 ml/min (p<0.0001).
Approximately 75% of enrolled subjects had at least one follow-up urine exam after
baseline. Those who did not have a follow-up exam were younger or more likely to be
women or of black race (p= 0.003, 0.02, and 0.02, respectively) (Table 2). There were,
however, no differences between those with and without follow-up with respect to CD4+
lymphocyte count, HIV-1 RNA level, blood pressure, kidney function, or urine protein
excretion.
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Clinical course for subjects without abnormal urine protein excretion at baseline
The proportions of subjects without abnormal urine protein excretion, microalbuminuria,
and proteinuria on next follow-up exam varied based on the results of their initial
examination (Figure 1). Almost 80% of subjects with no baseline abnormal urine protein
excretion continued to be without abnormality on follow-up. However, 15.7 % and 5.3 %
demonstrated microalbuminuria and proteinuria, respectively, on subsequent exams.
Clinical or demographic characteristics were not significantly different among subjects
without abnormal urine protein excretion at baseline who continued to be without
abnormality compared to those who developed microalbuminuria or proteinuria (Table 3a)
with the exception of CD4+ lymphocyte count. Subjects who developed proteinuria tended
to have a lower CD4+ lymphocyte count than those who continued to be without
abnormality (p=0.06).
Clinical course for subjects with microalbuminuria at baseline
Among subjects with microalbuminuria, a substantial proportion did not demonstrate any
abnormality on follow-up exam (46.5%) while 39.5% had continued microalbuminuria and
14.0 % demonstrated progression to proteinuria (Figure 1).
Subjects with baseline microalbuminuria who had subsequent urine examinations that
continued to reveal abnormalities (microalbuminuria or proteinuria) were slightly older
(p=0.003) and had slightly lower GFR (p=0.005) than those who had no urine abnormality
on follow-up exam (Table 3b). In a multivariable model, older age and lower GFR were
both associated with an increased risk of persistent abnormal urine examinations on follow-
up (age OR=1.66 per 10 year increase, p=0.03, GFR OR=1.14 per 10 cc/min decrease,
p=0.06).
Subjects without baseline proteinuria (i.e. those without abnormal urine protein excretion or
those with microalbuminuria) who developed proteinuria were more likely to have
microalbuminuria (p=0.001), a lower CD4+ lymphocyte count (p=0.06), and a higher
plasma HIV RNA level (p=0.03) than those who did not develop proteinuria (Table 3c). In
multivariate analysis among subjects without proteinuria at baseline, only microalbuminuria
was significantly associated with the development of proteinuria on follow-up (OR=2.9;
95% CI 1.5, 5.5; p=0.001). While both decreasing CD4+ lymphocyte count and increasing
plasma HIV RNA level were associated with an increasing risk for the development of
proteinuria in univariate analyses (p=0.06 and 0.04, respectively), these variables did not
maintain conventional levels of statistical significance when controlled for
microalbuminuria.
Sensitivity analysis for subjects with three urine measurements
Because the clinical diagnosis of microalbuminuria was recently defined as requiring two
consecutive measurements of elevated values, the above analyses were repeated using the
subset of subjects in the cohort who had at least three urine exams and in whom the first two
provided agreement as to the degree of protein excretion. The proportion of subjects who
maintained their level of urine protein excretion or progressed or regressed to other levels of
protein excretion was similar to the cohort overall (data not shown). The ability of two
consecutive values of microalbuminuria to predict overt proteinuria increased substantially
(OR= 21.7, 95% CI 10.8,43.8, p<0.001).
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This prospective cohort study demonstrates that a significant proportion of individuals
infected with HIV have microalbuminuria or proteinuria and that the presence of subtle
abnormalities like microalbuminuria portend an increased risk of potentially more clinically
relevant abnormalities such as proteinuria. Over time the development of either
microalbuminuria or proteinuria appeared to be associated with a lower CD4+ count or
higher HIV RNA level. It further demonstrates that following an initial positive test for
microalbuminuria subsequent urine may reveal no abnormality, particularly among younger
subjects and those with a higher GFR. Finally, as a practical message, these data suggest that
the use of a single urine exam might lead to misclassification and confirmation testing is an
important consideration.
This is the initial description of the predictive role that microalbuminuria may play in the
development of more clinically significant renal disease among HIV-infected individuals.
Prior to this study, multiple cross-sectional studies had found a varied prevalence of
microalbuminuria among patients with HIV infection of 10.9%, 19.4%, 29.8%, and 31.6%
(14-17) among patients without hypertension or evidence of other renal disease. Given the
associations between factors such as race, CD4+ lymphocyte count, and plasma HIV RNA
level, these variations likely reflect the distribution of these predictive parameters in the
population studied. Regardless of the exact prevalence, the proportion of patients with
microalbuminuria in contemporary populations is likely substantial.
With respect to the immunologic associations, this study is similar to a prior cross-sectional
analysis in which microalbuminuria was also associated with a lower CD4+ lymphocyte
count (17). In this cross-sectional study of HIV infected subjects with lipodystrophy, urine
albumin to creatinine ratios were measured and demonstrated to be associated with not only
CD4+ lymphocyte count, but also cardiovascular risk factors such as increased insulin
resistance and systolic blood pressure. This current cohort study confirms the association
between CD4+ lymphocyte count and microalbuminuria. The lack of association with blood
pressure here may simply reflect nonstandard measurements and lack of information
concerning use of antihypertensive medications.
The ability of microalbuminuria to predict future proteinuria in this study is similar to the
studies describing this relationship among patients with diabetes mellitus (3,4,18-21).
Additionally, a similar phenomenon of regression from microalbuminuria to a urine exam
that has no detectableprotein excretion as seen in this cohort has also been demonstrated
among persons with diabetes (19). Among patients with diabetes, 50.6% with
microalbuminuria demonstrated “regression” to normal protein excretion. Whether this
regression reflects effective treatment or a higher rate of false positives in the use of
microalbuminuria as a screening test cannot be determined from either this study or those in
diabetics. However, with respect to the relationship between microalbuminuria and
proteinuria, a key difference between this study and those assessing patients with diabetes
mellitus is time course. The time point at which microalbuminuria develops into overt
proteinuria cannot be truly assessed in either studies on diabetic nephropathy or using these
data based on the fact that the event is the measurement of protein excretion in the specimen
not the true date of progression. However the extent to which length of follow up can be
used as a surrogate for the rate of progression, it should be noted that the studies of patients
with diabetes mellitus had substantial lengths of follow-up (e.g. 7, 18 and 23 years) whereas
this current study tested urine measurements within a much shorter time frame. While
conservatively the time course of microalbuminuria transitioning into proteinuria may be
similar among persons with HIV as compared with diabetes mellitus, the current findings of
a significant association within 2 years of initial detection of microalbuminuria, suggests this
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process may be accelerated among persons with HIV. Further, with longer follow up it is
possible that the predictive ability of microalbuminuria is even stronger than that
demonstrated here.
While this study presents data regarding the development of microalbuminuria and its
progression to overt proteinuria among persons with HIV, it is not without limitation.
Medication information including the use of antihypertensives such as angiotensin
converting enzyme inhibitors and antiretroviral therapy shown to affect urine protein
excretion was not available. While one study suggested that antiretroviral therapy benefited
established proteinuria (22) and another demonstrated that women not treated with
antiretroviral therapy have a greater progression of their microalbumin excretion over time
as compared to women who were treated with highly active antiretroviral therapy (23),
information on the use of antiretrovirals is similarly not available. If the use of these
medications similarly slows the progression of microalbuminuria to overt proteinuria failure
to account for the increasing use of therapy over time would bias these findings towards the
null. So the relationships examined in this manuscript may be more significant than those
demonstrated.
The first subject was enrolled in this study in the year 2000. At that time and around the time
period during which this study was designed, the use of albumin to creatinine ratio in an
untimed urine specimen was felt to be an adequate screening strategy for patients with
diabetes mellitus (24-26). Recent trials have used more strict criteria for screening and
confirmation of the presence of abnormal urinary excretion of albumin (27). Clearly, the use
of a single urine specimen in this study may introduce misclassification bias primarily
between the groups without abnormal urine protein excretion and those with
microalbuminuria. While this method does mimic practically what may occur in the
screening of individuals in the course of their clinical care, it also may serve to bias these
results toward the null, potentially diluting an association that may be even more significant.
These data therefore underscore that the common clinical practice of utilizing a single urine
specimen should be carefully interpreted and consideration toward confirmation of a finding
such as microalbuminuria before therapy is instituted given. However, it should be noted
that when the data were analyzed in a manner consistent with the current criteria for the
diagnosis of microalbuminuria, the relationships were persistent and perhaps stronger.
Additionally, it should be noted in the application of these findings to clinical practice, that
proteinuria can also originate from a pathology that affects tubular resorption of the normal
filtered amount of protein. While microalbuminuria may similarly reflect a tubular process it
is used clinically to reflect early glomerular disease.
Another limitation of this study is that it is based on population of convenience rather than
the entire clinic population. While this should not affect the estimate of the predictive ability
of microalbuminuria, it likely affects the estimate of prevalence of microalbuminuria and
proteinuria. Therefore, it is recommended that prevalence estimates be interpreted
cautiously. Finally, this cohort cannot examine the link between microalbuminuria and
proteinuria and clinical outcomes such as mortality. While the link between proteinuria and
mortality is demonstrated in prior studies (6,7), it has not been examined among persons
with microalbuminuria. The inability of these data to examine this association is related to
the number of individuals who changed their care provider during the course of their follow-
up and subsequently did not present for additional clinical care after the visit in which they
provided their baseline sample. The lack of follow-up information on approximately one
quarter of the initial cohort does not allow the examination of the link between albuminuria
and mortality. This will need to be examined in additional studies. Subjects who did not
present for additional clinical care differed from those that did in terms of demographics
such as age and gender. Given that association between microalbuminuria and progression
Szczech et al. Page 6













to proteinuria did not appear to be confounded by either of these variables, the impact of this
loss to follow up must be considered but may not affect the conclusions substantively.
In summary, microalbuminuria is common in HIV infected persons and appears to be
associated with immunologic parameters such as CD4+ lymphocyte count. While patients
with microalbuminuria on initial evaluation may not continue to have similar findings on
subsequent exams (i.e. revert to normal levels of albumin excretion), there appears to be a
subgroup of persons partially identified by slightly older age and decreased GFR that have
persistent urinary protein excretion abnormalities. Finally, microalbuminuria is predictive of
the development of proteinuria. These findings may suggest a utility to the periodic
screening of persons with HIV for the presence of microalbuminuria. However, the next
integral step will be to determine if the efficacy of treatment strategies for albuminuria such
as ACE inhibitors, angiotensin receptor blockers, and antiretroviral therapy improve clinical
outcomes. Clinically, it should be considered that in the absence of a dedicated test for
microalbuminuria, it is not possible to discern between patients with or without elevated
levels of urinary albumin using only a urine dipstick. Given that microalbuminuria is a risk
factor for proteinuria, knowledge of its presence through dedicated testing might be
indicated to eventually guide clinicians to the optimal prevention of progression of renal
disease in HIV-infected persons.
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Figure 1. Flow diagram of urine examinations at baseline and follow up
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Table 1
Clinical and demographic characteristics of subjects by baseline urine exam
Variable No urinary abnormalities Microalbuminuria Proteinuria P-value
Number of patients 658 (69.4%) 191 (20.2%) 99 (10.4%)
Age (years)* 43.6 (9.1) 43.2 (9.2) 45.4 (9.7) 0.59 *
0.05 **
Gender
 Women 177 (26.9%) 63 (33.0%) 33 (33.3%) 0.15
 Men 480 (73.1%) 128 (66.0%) 66 (66.7%)
Race
 White 285 (43.3%) 76 (39.8%) 26 (26.3%) 0.02
 Black 351 (53.3%) 105 (55.0%) 67 (67.7%)
 Other 21 (3.2%) 10 (5.2%) 6 (6.0%)
CD4+ lymphocyte count (cells/ml) 464 (322) 403 (302) 269 (230) 0.02 *
0.0001 **
HIV-1 RNA level (copies/ml) 35,744 (110,060) 53,688 (146,848) 97,161 (195,999) 0.08 *
0.04 **
Systolic blood pressure (mmHg) 123 (13) 126 (18) 121 (23) 0.08 *
0.34 **
Diastolic blood pressure (mmHg) 80 (10) 82 (11) 83 (16) 0.03 *
0.62 **
Creatinine (mg/dL) 0.95 (0.40) 0.99 (0.36) 1.18 (0.82) 0.31 *
   SI units 83.98 (35.36) 87.56 (31.82) 104.31 (72.48) 0.005 **
Glomerular filtration rate (cc/min) by category
>=90 cc/min 445 (67.6%) 112 (58.6%) 48 (48.5%) <0.0001
60-90 cc/min 194 (29.5%) 64 (33.5%) 32 (32.3%)
< 60 cc/min 19 (2.9%) 15 (7.8%) 19 (19.2%)
Data is expressed as #(%) for categorical variables and mean (standard deviation) for continuous variables.
*
Comparison of subjects with no detectableurine protein excretion to those with microalbuminuria
**
Comparison of subjects with microalbuminuria to those with proteinuria
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Table 2
Clinical and demographic characteristics of subjects by the availability of a follow-up
urine exam
Variable Follow up examinations No follow up examination P-value
Number of patients 698 250
Age (years)* 44.2 (9.1) 42.2 (9.1) 0.003
Gender
 Women 187 (26.8%) 86 (34.4%) 0.02
 Men 511(73.2%) 163 (65.2%)
Race
 White 302 (43.3%) 85 (34.0%) 0.02
 Black 366 (52.4%) 157 (62.8%)
 Other 30 (4.3%) 7 (2.8%)
CD4+ lymphocyte count (cells/ml) 441 (319) 400 (302) 0.08
HIV-1 RNA level (copies/ml) 44,673 (133,949) 48,391 (118,115) 0.71
Systolic blood pressure (mmHg) 124 (16) 124 (13) 0.83
Diastolic blood pressure (mmHg) 81 (11) 80 (11) 0.58
Creatinine (mg/dL) 1.0 (0.4) 1.0 (0.6) 0.54
   SI units 88.4 (35.36) 88.4 (53.04)
Glomerular filtration rate (cc/min) by category
 >=90 cc/min 430 (61.6%) 175 (70.0%) 0.06
 60-90 cc/min 226 (32.4%) 64 (25.6%)
 <60 cc/min 42 (6.0%) 11 (4.4%)
Urine protein excretion
 No abnormality 492 (70.5%) 166 (66.4%) 0.08
 Microalbuminuria 129 (18.5%) 62 (24.8%)
 Proteinuria 77 (11.0%) 22 (8.8%)
Data is expressed as #(%) for categorical variables and mean (standard deviation) for continuous variables.
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